SCHEMBL13898149

SCHEMBL13898149

NCC(=O)Nc1cccc(Nc2ncc(Br)c(NCCc3c[nH]cn3)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 12/20 0.53
▸ MARK3 P27448 2/20 0.53
▸ MARK4 Q96L34 2/20 0.53
▸ AURKA O14965 1/20 0.53
▸ MET P08581 4/20 0.47
▸ ALK Q9UM73 4/20 0.47
▸ PDPK1 O15530 5/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ STK17A Q9UEE5 1/20 0.45
▸ NUAK1 O60285 1/20 0.44
▸ STK16 O75716 1/20 0.44
▸ NTRK1 P04629 1/20 0.44
▸ CSNK2A2 P19784 1/20 0.44
▸ TYK2 P29597 1/20 0.44
▸ BMPR2 Q13873 1/20 0.44
▸ AAK1 Q2M2I8 1/20 0.44
▸ NUAK2 Q9H093 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ BMP2K Q9NSY1 1/20 0.44
▸ ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13897930 0.91 TBK1 (0.53) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL13897853 0.91 TBK1 (0.55) TBK1MARK3MARK4AURKAALK
SCHEMBL13897737 0.90 TBK1 (0.52) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL13897962 0.90 TBK1 (0.52) TBK1MARK3MARK4AURKAMET
SCHEMBL13897910 0.89 TBK1 (0.55) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL3866798 0.89 TBK1 (0.55) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL13897876 0.89 TBK1 (0.52) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL14112812 0.89 TBK1 (0.51) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL3865639 0.89 TBK1 (0.54) TBK1MARK3MARK4AURKAPDPK1
SCHEMBL13898092 0.88 TBK1 (0.51) TBK1MARK3MARK4AURKAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US disclosed
Send feedback